Skip to main navigation menu Skip to main content Skip to site footer

Original article

Vol. 140 No. 4546 (2010)

The impact of infections on critically ill acute heart failure patients: an observational study

  • M Streit
  • F Businger
  • ER Schmid
  • F Follath
DOI
https://doi.org/10.4414/smw.2010.13125
Cite this as:
Swiss Med Wkly. 2010;140:w13125
Published
08.11.2010

Summary

BACKGROUND: Hospitalised patients with acute heart failure (AHF) suffer from a high morbidity and mortality, which might, at least partly, be influenced by concomitant infections. The aim of this observational study was to investigate the impact of infections on the clinical course of critically ill patients with AHF, both present on intensive care unit (ICU) admission and acquired during the ICU stay.

METHODS: From 178 consecutive AHF patients, 76 were treated medically and 21 required emergency cardiac surgery. The remaining 81 patients, who underwent elective cardiac surgery, were excluded from the assessment of infections on ICU admission, but were included in the analysis of nosocomial infections during the ICU stay.

RESULTS: A total of 16% of patients (16/97) had infections on ICU admission. These patients had longer ICU (6 vs. 3 days, = 0.04) and hospital (19 vs. 11 days, p = 0.04) stays than patients without infections. Although not statistically significant, there was a trend for increased mortality at 30 days (44% vs. 24%, p = 0.13) and 6 months (57% vs. 31%, p = 0.13) in AHF patients with infections on ICU admission. Infection complications during the ICU stay occurred in 17% (30/178) of AHF patients and significantly increased their mortality at 30 days (33% vs. 14%, p = 0.02) and 6 months (41% vs. 18%, p = 0.02).

CONCLUSIONS: In this observational study, infections present on ICU admission or occurring during the ICU stay had a negative impact on the morbidity and mortality of critically ill patients with AHF. Future studies are needed to gain a better understanding of the interactions between heart failure and infections, as a better knowledge of this field may have an important therapeutic potential.

References

  1. Nieminen MS, Brutsaert D, Dickstein K, Drexler H, Follath F, Harjola V-P, et al. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J. 2006;27:2725–36.
  2. Rudiger A, Harjola V-P, Müller A, Mattila E, Säila P, Nieminen M, et al. Acute heart failure: clinical presentation, one-year mortality and prognostic factors. Eur J Heart Fail. 2005;7:662–70.
  3. Siirila-Waris K, Lassus J, Melin J, Peuhkurinen K, Nieminen MS, Harjola VP. Characteristics, outcomes, and predictors of 1-year mortality in patients hospitalized for acute heart failure. Eur Heart J. 2006;27:3011–7.
  4. Tavazzi L, Maggioni A, Lucci D, Cacciatore G, Ansalone G, Olivia F, et al. Nationwide survey on acute heart failure in cardiology ward services in Italy. Eur Heart J. 2006;27:1207–15.
  5. Zannad F, Mebazaa A, Juillière Y, Cohen-Solal A, Guize L, Alla F, et al. Clinical profile, contemporary management and one-year mortality in patients with severe acute heart failure syndromes: The EFICA study. Eur J Heart Fail. 2006;8:697–705.
  6. Safdar N, Dezfulian C, Collard HR, Saint S. Clinical and economic consequences of ventilator-associated pneumonia: a systematic review. Crit Care Med. 2005;33:2184–93.
  7. Rudiger A, Businger F, Streit M, Schmid ER, Maggiorini M, Follath F. Presentation and outcome of critically ill medical and cardiac-surgery patients with acute heart failure. Swiss Med Wkly. 2009;139:110–6.
  8. Nieminen MS, Bohm M, Cowie MR, Drexler H, Filippatos GS, Jondeau G, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure. The Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26:384–416.
  9. Rudiger A, Fischler M, Harpes P, Gasser S, Hornemann T, von Eckardstein A, et al. In critically ill patients, B-type natriuretic peptide (BNP) and N-terminal pro-BNP levels correlate with C-reactive protein values and leukocyte counts. Int J Cardiol. 2008;126:28–31.
  10. Rudiger A, Gasser S, Fischler M, Hornemann T, Von Eckardstein A, Maggiorini M. Comparable increase of B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide levels in patients with severe sepsis, septic shock, and acute heart failure. Crit Care Med. 2006;34:2140–4.
  11. The American Thoracic Society and the Infecious Disease Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388–416.
  12. Masterton RG, Galloway A, French G, Street M, Armstrong J, Brown E, et al. Guidelines for the management of hospital-acquired pneumonia in the UK: report of the working party on hospital-acquired pneumonia of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother. 2008;62:5–34.
  13. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA. 1993;270:2957–63.
  14. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34:1589–96.
  15. Rudiger A, Singer M. Mechanisms of sepsis-induced cardiac dysfunction. Crit Care Med. 2007;35:1599–608.
  16. Chen D, Assad-Kottner C, Orrega C, Torre-Amione G. Cytokines and acute heart failure. Crit Care Med. 2008;36:S9–16.
  17. Paulus WJ. How are cytokines activated in heart failure? Eur J Heart Fail. 1999;1:309–12.
  18. Peschel T, Schoenauer M, Thiele H, Anker SD, Schuler G, Niebauer J. Invasive assessment of bacterial endotoxin and inflammatory cytokines in patients with acute heart failure. Eur J Heart Fail. 2003;5:609–14.
  19. Kumar A, Haery C, Paladugu B, Kumar A, Symeoneides S, Taiberg L, et al. The duration of hypotension before the initiation of antibiotic treatment is a critical determinant of survival in a murine model of Escherichia coli septic shock: association with serum lactate and inflammatory cytokine levels. J Infect Dis. 2006;193:251–8.
  20. Eggimann P, Pittet D. Infection control in the ICU. Chest. 2001;120:2059–93.
  21. Kohsaka S, Menon V, Lowe AM, Lange M, Dzavik V, Sleeper LA, et al. Systemic inflammatory response syndrome after acute myocardial infarction complicated by cardiogenic shock. Arch Int Med. 2005;165:1643–50.
  22. Zilberberg MD, Shorr AF, Kollef MH. Implementing quality improvements in the intensive care unit: ventilator bundle as an example. Crit Care Med. 2009;37:305–9.
  23. O’Grady NP, Alexander M, Dellinger EP, Gerberding JL, Heard SO, Maki DG, et al. Guidelines for the prevention of intravascular catheter-related infections. Infect Control Hosp Epidemiol. 2002;23:759–69.
  24. Pronovost P, Needham D, Berenholtz S, Sinopoli D, Chu H, Cosgrove S, et al. An intervention to decrease catheter-related bloodstream infections in the ICU. N Engl J Med. 2006;355:2725–32.
  25. de Smet AM, Kluytmans JA, Cooper BS, Mascini EM, Benus RF, van der Werf TS, et al. Decontamination of the digestive tract and oropharynx in ICU patients. N Engl J Med. 2009;360:20–31.
  26. de Jonge E, Schultz MJ, Spanjaard L, Bossuyt PM, Vroom MB, Dankert J, et al. Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial. Lancet. 2003;362:1011–6.
  27. Pugin J, Auckenthaler R, Lew DP, Suter PM. Oropharyngeal decontamination decreases incidence of ventilator-associated pneumonia. A randomized, placebo-controlled, double-blind clinical trial. JAMA. 1991;265:2704–10.
  28. Felker GM, Cotter G. Unraveling the pathophysiology of acute heart failure: an inflammatory proposal. Am Heart J. 2006;151:765–7.
  29. Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res. 2002;91:988–98.
  30. Hasper D, Hummel M, Kleber FX, Reindl I, Volk HD. Systemic inflammation in patients with heart failure. Eur Heart J. 1998;19:761–5.